Cancer Drugs

Inhibitor of Bcl-2 family proteins induced regression of solid tumors

Published in Cancer Weekly, July 12th, 2005

An inhibitor of the Bcl-2 family of proteins was shown to induce regression of solid tumors.

"Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X-L and Bcl-2, are overexpressed in many cancers and contribute to tumor initiation, progression and resistance to therapy. Bcl-X-L expression correlates with chemoresistance of tumor cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival," scientists in the United States reported.

"The development of inhibitors of these proteins as potential anti-cancer therapeutics has been...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-07-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry